Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma

NCT03084640 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma

Interventions

DRUG: CMP-001
DRUG: Pembrolizumab
DRUG: CMP-001

Sponsor

Regeneron Pharmaceuticals